Evaluation and Management of Adult ADPKD
Begin with abdominal ultrasound as the first-line diagnostic test for adults at risk, using age-specific cyst criteria to confirm or exclude ADPKD, followed by MRI or genetic testing if ultrasound results are equivocal or atypical features are present 1.
Diagnostic Approach
For Adults with Positive Family History
Start with kidney ultrasound using these age-specific diagnostic criteria 1:
- Ages 15-39 years: ≥3 total cysts confirms ADPKD; ≤1 cyst rules it out
- Ages 40-59 years: ≥2 cysts in each kidney confirms ADPKD; ≤2 total cysts rules it out
- Age ≥60 years: ≥4 cysts in each kidney confirms ADPKD
If ultrasound is equivocal or shows atypical features, proceed to:
- MRI (for ages 16-40: >10 total cysts confirms, <5 cysts rules out) 1
- Genetic testing targeting PKD1, PKD2, and minor genes using ACMG criteria 1
For Adults with Incidentally Detected Cysts (No Family History)
When kidney/liver cysts are found incidentally 1:
- Few cysts + normal kidney function/size + no extrarenal features: Proceed directly to genetic testing
- Multiple cysts OR discordant imaging/GFR OR atypical features: Obtain kidney MRI first, then genetic testing if diagnosis remains uncertain
Genetic testing is particularly valuable when 1:
- Few kidney cysts present
- Variable intrafamilial disease severity
- Negative family history
- Young living-related kidney donors (<30 years) being evaluated
- Family planning considerations
Risk Stratification
Use the Mayo Imaging Classification (MIC) to predict kidney function decline and timing of kidney failure 1. This requires:
- Height-adjusted total kidney volume measured by MRI or CT
- Classification into typical (Class 1) vs atypical (Class 2) ADPKD
- For Class 1 patients: stratification into groups 1A-1E indicating accelerating decline
The causal gene determines severity: PKD1 truncating mutations are most severe (kidney failure in 50s), PKD1 nontruncating mutations are intermediate, and PKD2 mutations are milder (kidney failure in 70s) 1.
Disease-Modifying Treatment
Tolvaptan is the cornerstone therapy for patients at high risk of rapid progression 1. The evidence shows:
- Net eGFR benefit: 1.3 mL/min/1.73m² per year preserved (95% CI: 1.0-1.7)
- Reduced total kidney volume growth: 2.7% less per year (95% CI: -3.3% to -2.1%)
- Reduced complications: Lower rates of UTI, kidney stones, hematuria, and kidney pain 1
Critical Tolvaptan Management Points 1:
Initiation requirements:
- Adequate water intake to replace urinary losses
- Patient education on "sick-day plan"
When to skip doses:
- Limited water access
- Increased fluid losses (vomiting, diarrhea)
- Activities in warm weather
- Any volume depletion risk
Counseling essentials:
- Drink sugar-free, fat-free liquids
- Adopt low-sodium intake (reduces polyuria)
- Expect small, reversible eGFR reduction initially (reflects reduced hyperfiltration)
Comprehensive Management
Blood Pressure Control
Target blood pressure control with RAAS blockade, sodium restriction, and maintenance of healthy body weight 2.
Symptom Management
Screen routinely for 3:
- Pain: Use validated tools (ADPKD-Pain and Discomfort Scale, APAT)
- Fatigue: Assess with FACIT-Fatigue Scale (affects up to 74% of early-stage patients)
- Psychological distress: 30% screen positive for mood disorders
- Body image concerns: 30-40% report embarrassment from abdominal enlargement
Functional limitations appear early - up to 74% of early-stage patients adjust daily activities 3. Monitor functional capacity and refer for physical/occupational therapy when appropriate.
Extrarenal Manifestations
Polycystic liver disease is the most frequent extrarenal manifestation 1. Screen for and manage hepatic cysts, particularly in women.
Intracranial aneurysms require screening in high-risk patients (family history of ICA or subarachnoid hemorrhage) 4.
Kidney Replacement Therapy
Preemptive living-donor kidney transplantation is the preferred treatment for kidney failure 1. Key considerations:
- Perform kidney imaging within 1 year before anticipated transplantation to rule out solid/complex cystic lesions
- Use standard immunosuppressive protocols
- Native nephrectomy only for specific indications: severe symptoms, recurrent infection/bleeding, insufficient space for graft, suspected malignancy
- If nephrectomy needed: perform at time of or after transplantation (never before), using hand-operated laparoscopic technique 1
Peritoneal dialysis is viable but use caution with massive kidney/liver enlargement or abdominal wall hernias 1.
Common Pitfalls
- Don't rely on ultrasound alone when results are equivocal - proceed to MRI or genetic testing
- Don't delay tolvaptan in high-risk patients due to concerns about polyuria - proper counseling and sick-day planning mitigate this
- Don't dismiss fatigue and pain as "just part of the disease" - these significantly impact quality of life and require active management
- Don't forget pre-counseling before genetic testing - discuss benefits, risks, and implications for family members 1